Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $782.7 million.

  • Autolus Therapeutics' Liabilities and Shareholders Equity fell 20.01% to $661.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year decrease of 1.55%. This contributed to the annual value of $782.7 million for FY2024, which is 108.51% up from last year.
  • Autolus Therapeutics' Liabilities and Shareholders Equity amounted to $782.7 million in FY2024, which was up 108.51% from $375.4 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Liabilities and Shareholders Equity ranged from a high of $782.7 million in FY2024 and a low of $375.4 million during FY2023.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $490.3 million (2022), whereas its average is $549.5 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Liabilities and Shareholders Equity decreased by 23.43% in 2023, and later surged by 108.51% in 2024.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Liabilities and Shareholders Equity stood at $405.6 million in 2021, then increased by 20.89% to $490.3 million in 2022, then fell by 23.43% to $375.4 million in 2023, then surged by 108.51% to $782.7 million in 2024.